Navigation Links
Drug designer
Date:7/8/2011

Protease inhibitor drugs are one of the major weapons in the fight against HIV, the virus that causes AIDS, but their effectiveness is limited as the virus mutates and develops resistance to the drugs over time. Now a new tool has been developed to help predict the location of the mutations that lead to drug resistance.

First discovered in 1995, protease inhibitor drugs have dramatically reduced the number of AIDS deaths. Taken in combination with two other anti-HIV drugs, protease inhibitors work by halting the action of the protease enzyme, a protein produced by HIV that is necessary for replication of the virus. However, almost half of HIV patients who initially respond to treatment with protease inhibitors develop drug-resistance strains and stop responding to treatment within eight to 10 months.

Currently there are nine FDA approved protease inhibitors, and 21 most common drug-resistant mutations.

The main reason for the short-term effectiveness of the drug has to do with the evolution of the drug within the body, said the study's author, Yi Mao, a postdoctoral fellow at the National Institute for Mathematical and Biological Synthesis.

In the new study, published today in the journal BMC Structural Biology, Mao used a mathematical modeling technique called elastic network modeling to examine the physical properties and interactions of the proteins. The model reveals where mutations are occurring during the evolution of the HIV-virus proteins and how these mutations help the virus survive.

"With this kind of knowledge, better strategies for designing anti-HIV drugs could be developed," Mao said.

HIV kills the body's immune system cells, called CD4 cells. Once the number of CD4 cells dips below 200, an HIV patient enters the last stage of his or her disease: Acquired Immune Deficiency Syndrome, or AIDS. The first cases of AIDS were reported thirty years ago. Since then, more than 60 million people have been infected with HIV, and mor
'/>"/>

Contact: Catherine Crawley
ccrawley@nimbios.org
865-974-9350
National Institute for Mathematical and Biological Synthesis (NIMBioS)
Source:Eurekalert

Page: 1 2

Related biology news :

1. Consumers desire more genetic testing, but not designer babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... 2012 Childhood Obesity , a peer-reviewed journal from Mary ... dedicated to the role that schools can and should ... eating habits to help stem the tide of the ... provides comprehensive coverage of food policy, systems, and programs ...
... becomes extinct, other predatory species could soon follow, according to ... a University of Exeter team has now carried out the ... 2012) in the Royal Society journal Biology Letters , ... can indirectly cause another to become extinct. The University of ...
... Biofuels and Texas AgriLife Research, part of The Texas ... develop and commercialize cellulosic feedstocks for the production of ... diverse high biomass energy crop breeding program and BP ... companies growing commercial-scale biomass crops for liquid fuels. ...
Cached Biology News:School food -- on the front line in the fight against childhood obesity 2Study proves that 1 extinction leads to another 2BP Biofuels, Texas AgriLife Research sign agreement to advance biofuel feedstock development 2
(Date:4/1/2015)... Canada,s Research-Based Pharmaceutical Companies (Rx&D) acknowledges the ... Cost Drivers of Public Drug Plans in Canada ... rates of change in drug costs have been steadily declining ... 2012/13 for a number of select public drug plans. But ... medicines without considering their overall impact on the system and ...
(Date:4/1/2015)... 2015 Synthetic Biologics, Inc. (NYSE MKT: ... infections and diseases, with a focus on protecting ... the development of SYN-004, the Company,s candidate therapy ... within the gastrointestinal (GI) tract and maintain the ... prevention of C. difficile infection, antibiotic-associated ...
(Date:4/1/2015)... The concept of “spot reducing” areas is ... Founder of Fasciology, Ashley Black, says that even the idea ... of having to wait for the whole fat system to ... to fat cooling procedures, the only well known way ... which is a highly invasive procedure.” It is common knowledge ...
(Date:3/31/2015)... -- CytoSorbents Corporation (NASDAQ CM: CTSO), a critical ... critically-ill and cardiac surgery patients in multiple countries ... results for the fiscal year ending December 31, ... were a record $3.1M, an increase of $2.3M ... $0.8M Highlights for the Year Ending December 31, ...
Breaking Biology Technology:Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 2Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 3Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 4Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 2Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 3CytoSorbents Reports Record 2014 Revenue 2CytoSorbents Reports Record 2014 Revenue 3CytoSorbents Reports Record 2014 Revenue 4CytoSorbents Reports Record 2014 Revenue 5CytoSorbents Reports Record 2014 Revenue 6CytoSorbents Reports Record 2014 Revenue 7CytoSorbents Reports Record 2014 Revenue 8CytoSorbents Reports Record 2014 Revenue 9CytoSorbents Reports Record 2014 Revenue 10CytoSorbents Reports Record 2014 Revenue 11
... Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) today ... the Company,s request for an,extension until December 3, ... market capitalization requirement of $35 million or the ... order to remain,listed. There can be no assurance ...
... Aortic ... Aneurysms, ... of Vascular Surgery was the first to implant, in,Phoenix, the Powerlink ... aortic aneurysms (AAA). The procedure was,performed at Arizona Heart Hospital by ...
... BOSTON, Oct. 31 PAREXEL International,Corporation (Nasdaq: ... at the,Oppenheimer 19th Annual Healthcare Conference in New ... Financial Officer will be making,a formal presentation on ... 3,2008., The presentation will be available under ...
Cached Biology Technology:Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements 2Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval 2Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval 3PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference 2